Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant...

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Urgent need for new agents against drug-resistant bacteria like MRSA.
• Existing antibiotics face challenges with resistance and immune response.
• Desirable properties include potency, selectivity, low resistance potential, and synergy.

Purpose of the Study:

• To analyze the antibacterial potential of F12, a genetically engineered anti-MRSA lysin.
• To evaluate F12's properties, including potency, selectivity, and synergy with standard-of-care (SOC) antibiotics.
• To investigate F12's ability to resensitize MRSA to beta-lactam antibiotics.

Main Methods:

• Genetic engineering of F12 to evade immune responses.
• In vitro and in vivo testing of F12's antibacterial activity.
• Assessment of synergy between F12 and SOC antibiotics.
• Evaluation of cross-resistance between F12 and beta-lactams.

Main Results:

• F12 demonstrated high potency and rapid action against MRSA.
• F12 exhibited narrow selectivity against pathogenic staphylococci.
• F12 showed synergy with multiple SOC antibiotics.
• Resistance to F12 and beta-lactams was mutually exclusive.
• F12 resensitized resistant MRSA strains to beta-lactams in vitro and in vivo.

Conclusions:

• F12 is a promising novel agent for treating MRSA infections.
• Combinations of F12 and SOC antibiotics represent a viable strategy for refractory S. aureus infections.
• F12's ability to overcome existing resistance mechanisms is a key advantage.